HC Wainwright restated their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $15.00 target price on the stock. Acumen Pharmaceuticals Stock Performance Shares of NASDAQ ABOS traded down $0.04 during trading on Wednesday, hitting $3.76. The company […]

Related Keywords

Chicago , Illinois , United States , , Acumen Pharmaceuticals , Analyst Recommendations For Acumen Pharmaceuticals , Jump Financial , Intrepid Financial Planning Group , Citigroup Inc , Acumen Pharmaceuticals Stock Performance , Sg Americas Securities , Chicago Partners Investment Group , Acumen Pharmaceuticals Inc , News Ratings For Acumen Pharmaceuticals Daily , Free Report , Get Free Report , Partners Investment Group , Financial Planning Group , Acumen Pharmaceuticals Daily ,